Form 4: Abeona Therapeutics CEO Vishwas Seshadri Reports Stock Transaction

Abeona Therapeutics CEO Vishwas Seshadri reports disposition of shares to cover tax obligations upon vesting of restricted stock.

Summary

• On June 5, 2024, Vishwas Seshadri, CEO of Abeona Therapeutics, reported a transaction involving common stock.
• Seshadri disposed of 38,621 shares at a price of $4.52 per share to cover tax withholding obligations.
• Following the transaction, Seshadri directly owns 498,936 shares of Abeona Therapeutics.
• The transaction was executed under Rule 16b-3(e), exempting it from certain regulations.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing, indicating standard executive compensation practices. It doesn't inherently suggest positive or negative sentiment, but the continued ownership stake is a neutral signal.

Industry Context

Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.

Comparison to Industry Standards

• Similar filings are routinely made by executives at comparable biotech companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics when they exercise stock options or have restricted stock units vest.
• The number of shares sold to cover taxes is typical for executives with significant equity compensation.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding executive stock ownership.
• The sale of shares to cover taxes has a minimal impact on the company's operations or financial condition.

Key Dates